 | Up a level |
Munzone, E.; Giobbie-Hurder, A.; Gusterson, B. A.; Mallon, E.; Viale, G.; Thürlimann, B.; Ejlertsen, B.; Macgrogan, G.; Bibeau, F.; Lelkaitis, G.; Price, K. N.; Gelber, R. D.; Coates, A. S.; Goldhirsch, A.; Colleoni, M. (2015). Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. Annals of oncology, 26(12), pp. 2442-2449. Oxford University Press 10.1093/annonc/mdv391
Huober, J.; Cole, B. F.; Rabaglio, Manuela; Giobbie-Hurder, A.; Wu, J.; Ejlertsen, B.; Bonnefoi, H.; Forbes, J. F.; Neven, P.; Láng, I.; Smith, I.; Wardley, A.; Price, K. N.; Goldhirsch, A.; Coates, A. S.; Colleoni, M.; Gelber, R. D.; Thürlimann, B. (2014). Symptoms of endocrine treatment and outcome in the BIG 1-98 study. Breast cancer research and treatment, 143(1), pp. 159-169. Springer 10.1007/s10549-013-2792-7
Viale, G.; Giobbie-Hurder, A.; Gusterson, B. A.; Maiorano, E.; Mastropasqua, M. G.; Sonzogni, A.; Mallon, E.; Colleoni, M.; Castiglione-Gertsch, M.; Regan, M. M.; Price, K. N.; Brown, R. W.; Golouh, R.; Crivellari, D.; Karlsson, P.; Öhlschlegel, C.; Gelber, R. D.; Goldhirsch, A.; Coates, A. S. (2009). Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer. Annals of oncology, 21(2), pp. 245-254. Oxford University Press 10.1093/annonc/mdp317
